Neurocrine Biosciences
NBIX
#1468
Rank
C$20.03 B
Marketcap
C$200.94
Share price
-0.24%
Change (1 day)
2.48%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): C$6.01

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$5.89. In 2024 the company made an earnings per share (EPS) of C$4.62 an increase over its 2023 EPS that were of C$3.47.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$6.0130.1%
2024C$4.6233.07%
2023C$3.4757.76%
2022C$2.2069.47%
2021C$1.30-78.21%
2020C$5.96990%
2019C$0.5581.82%
2018C$0.30-113.5%
2017C-$2.230.62%
2016C-$2.2257.28%
2015C-$1.4125.61%
2014C-$1.1218.84%
2013C-$0.94-1085.71%
2012C$0.09573

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
C$0.04103-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.42-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
C-$40.89-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$28.06 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$1.85-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$2.35-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$2.34-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.78-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA